The dual c-Met/VEGFR2 inhibitor foretinib augments chemotherapy response in preclinical models of gastric cancer

被引：1
|
作者：
Awasthi, Niranjan [1 ]
Grojean, Meghan [1 ]
Monahan, Sheena [1 ]
Hassan, Sazzad [1 ]
von Holzen, Urs [1 ]
Schwarz, Margaret A. [1 ]
Schwarz, Roderich E. [1 ]
机构：
[1] Indiana Univ Sch Med, South Bend, IN USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-5807
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5807
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study
    Jhawer, M. P.
    Kindler, H. L.
    Wainberg, Z. A.
    Hecht, J. R.
    Kerr, R. O.
    Ford, J. M.
    Henderson, C.
    Mueller, T.
    Keer, H. N.
    Shah, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] A selective inhibitor targeting c-Met receptor tyrosine kinase in gastric cancer
    Park, Byung Hee
    Yun, Sun-Mi
    Jung, Kyung Hee
    Lee, Hyunseung
    Hong, Soon-Sun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 350 - 350
  • [33] AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma.
    Zito Marino, F.
    Accardo, M.
    Poziello, G.
    Ronchi, A.
    Ciaramella, V.
    Vicidomini, G.
    Santini, M.
    Morgillo, F.
    Franco, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S759 - S759
  • [34] Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer
    Yang, Ju
    Yan, Jing
    Shao, Jie
    Xu, Qiuping
    Meng, Fanyan
    Chen, Fangjun
    Ding, Naiqing
    Du, Shiyao
    Zhou, Shujuan
    Cai, Juan
    Wang, Qin
    Liu, Baorui
    ONCOTARGETS AND THERAPY, 2019, 12 : 9757 - 9765
  • [35] Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
    Hsu, Jeff
    Chong, Colin
    Serrill, Jeffrey
    Goon, Levina
    Balayan, Joan
    Johnson, Eric N.
    Lorenzana, Grachelle
    Wu, Sharon
    Leong, Kevin G.
    Yun, Theodore J.
    Wang, Yong
    Jiang, Faming
    Bannen, Lynne
    Lamb, Peter
    Xu, Wei
    Yu, Peiwen
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (02) : 179 - 191
  • [36] Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
    Ai, Jing
    Chen, Yi
    Peng, Xia
    Ji, Yinchun
    Xi, Yong
    Shen, Yanyan
    Yang, Xinying
    Su, Yi
    Sun, Yiming
    Gao, Yinglei
    Ma, Yuchi
    Xiong, Bing
    Shen, Jingkang
    Ding, Jian
    Geng, Meiyu
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (04) : 751 - 762
  • [37] E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models
    Nakagawa, Takayuki
    Tohyama, Osamu
    Yamaguchi, Atsumi
    Matsushima, Tomohiro
    Takahashi, Keiko
    Funasaka, Setsuo
    Shirotori, Shuji
    Asada, Makoto
    Obaishi, Hiroshi
    CANCER SCIENCE, 2010, 101 (01): : 210 - 215
  • [38] Efficacy of VEGFR2 targeted mAb therapy in preclinical cancer models resistant to antiangiogenic therapy
    Surguladze, D.
    Plym, M. J.
    Malaby, J.
    Prewett, M.
    Rutstein, M.
    Schwartz, J.
    Lu, D.
    Witte, L.
    Tonra, J. R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 75 - 75
  • [39] A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
    M Yashiro
    T Nishii
    T Hasegawa
    T Matsuzaki
    T Morisaki
    T Fukuoka
    K Hirakawa
    British Journal of Cancer, 2013, 109 : 2619 - 2628
  • [40] A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
    Yashiro, M.
    Nishii, T.
    Hasegawa, T.
    Matsuzaki, T.
    Morisaki, T.
    Fukuoka, T.
    Hirakawa, K.
    BRITISH JOURNAL OF CANCER, 2013, 109 (10) : 2619 - 2628
12345